Zydus Cadila gets USFDA nod for Glyburide and Metformin Hcl Tablets

01 Mar 2016 Evaluate

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Glyburide and Metformin Hcl Tablets USP in strengths of 1.25/250, 2.5/500 and 5/500 mg. The drug falls in the anti-diabetics segment and the group's formulations manufacturing site at Baddi will be producing the drug for the US market.

The group now has 103 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

913.90 -7.35 (-0.80%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×